Among other things, the Inflation Reduction Act established Medicare drug price negotiation for selected products, inflation-based rebate obligations, and a redesign of the Medicare Part D benefit, including a manufacturer discount program that became effective January 1, 2025. In addition, the first negotiated Medicare prices became effective on January 1, 2026. These and other current or future healthcare reform measures may reduce the commercial opportunity for our products, increase our compliance burdens, or otherwise adversely affect our business, financial condition and results of operations.
All entries for: Hematology
March 16, 2026
Assertio Holdings
Neutral Outlook
Lake Forest, IL
51-200 employees
In addition, the Inflation Reduction Act of 2022 (“IRA”) contains provisions intended to lower beneficiary drug spending. Beginning in 2023, the IRA enables Medicare to negotiate prescription drug prices with manufacturers of certain high-cost drugs for the first time. Each year, CMS will select and negotiate a preset number of high-spend drugs and biologics that are covered under Medicare Part B and Part D that do not have generic or biosimilar competition. In January 2025, CMS announced a list of fifteen additional Medicare Part D drugs that will be subject to price negotiations. To date, none of our products have been selected to be subject to price negotiations.
Disease Area: Hematology, Neurological Diseases, Oncology
Drug Type: Small Molecule
March 12, 2026
Adicet Bio, Inc.
Neutral Outlook
Redwood City, CA
51-200 employees
Although the effects of the IRA on our business and the healthcare industry in general is not yet known, we are taking into consideration the potential impact of the IRA on our development and commercialization activities.
Disease Area: Hematology, Immune Diseases, Oncology
Drug Type: Biologic
March 12, 2026
Precision Biosciences Inc
Neutral Outlook
Durham, NC
51-200 employees
While the impact of the IRA on the pharmaceutical industry cannot yet be fully determined, it is likely to be significant.
Disease Area: Antiviral, Hematology, Immune Diseases, Infectious Diseases, Neurological Diseases, Rare Diseases
Drug Type: Biologic
March 10, 2026
ADC Therapeutics SA-Switzerland
Neutral Outlook
Switzerland
51-200 employees
Thus, while it is unclear how some provisions of the IRA will be implemented, we are liable for Part B inflation rebates for ZYNLONTA under the IRA, which has and will continue to negatively impact our gross-to-net adjustment for ZYNLONTA sales.
Disease Area: Hematology, Oncology
Drug Type: Biologic